Evidence map›Paper›PMID 34192127›Full record

ArticleGE Portuguese journal of gastroenterology2021

Impact of Liver Test Abnormalities and Chronic Liver Disease on the Clinical Outcomes of Patients Hospitalized with COVID-19.

Mónica Garrido, Tiago Pereira Guedes, Joana Alves Silva, Daniela Falcão, Inês Novo, Sara Archer, Marta Rocha, Luís Maia, Rui Sarmento-Castro, Isabel Pedroto

Open access · diamondAbstract read
In one paragraph

Article in GE Portuguese journal of gastroenterology, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed, 2 pooled it
1.0field-weighted citation impact, top 22% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed, 2 syntheses or guidelines pooled it, 17 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Review
  4. Article
  5. Review
  6. Outcomes of COVID-19 among patients with liver disease.World journal of gastroenterology · 2023
    Review
  7. Review
  8. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 2 institutions in 1 country.

Mónica GarridoDepartment of Gastroenterology, Centro Hospitalar Universitário do Porto, Porto, Portugal.
Tiago Pereira GuedesDepartment of Gastroenterology, Centro Hospitalar Universitário do Porto, Porto, Portugal.
Joana Alves SilvaDepartment of Gastroenterology, Centro Hospitalar Universitário do Porto, Porto, Portugal.
Daniela FalcãoDepartment of Gastroenterology, Centro Hospitalar Universitário do Porto, Porto, Portugal.
Inês NovoDepartment of Gastroenterology, Centro Hospitalar Universitário do Porto, Porto, Portugal.
Sara ArcherDepartment of Gastroenterology, Centro Hospitalar Universitário do Porto, Porto, Portugal.
Marta RochaDepartment of Gastroenterology, Centro Hospitalar Universitário do Porto, Porto, Portugal.
Luís MaiaDepartment of Gastroenterology, Centro Hospitalar Universitário do Porto, Porto, Portugal.
Rui Sarmento-CastroDepartment of Infectious Diseases, Centro Hospitalar Universitário do Porto, Porto, Portugal.
Isabel PedrotoDepartment of Gastroenterology, Centro Hospitalar Universitário do Porto, Porto, Portugal.
Centro Hospitalar do Porto · PTUniversidade do Porto · PT

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

BACKGROUND AND

aimsThe impact of SARS-CoV-2 infection on the liver and the possibility of chronic liver disease (CLD) as a risk factor for COVID-19 severity is not fully understood. Our goal was to describe clinical outcomes of COVID-19 inpatients regarding the presence of abnormal liver tests and CLD.

methodsA retrospective analysis of patients with SARS-CoV-2 infection, hospitalized in a tertiary center in Portugal, was performed. Studied outcomes were disease and hospitalization length, COVID-19 severity, admission to intensive care unit (ICU) and mortality, analyzed by the presence of abnormal liver tests and CLD.

resultsWe included 317 inpatients with a mean age of 70.4 years, 50.5% males. COVID-19 severity was moderate to severe in 57.4% and critical in 12.9%. The mean disease length was 37.8 days, the median hospitalization duration 10.0 days and overall mortality 22.8%. At admission, 50.3% showed abnormal liver tests, and 41.5% showed elevated aminotransferase levels, from which 75.4% were mild. Elevated aminotransferase levels at admission were associated with COVID-19 severity (78.7 vs. 63.3%,

conclusionsLiver test abnormalities in COVID-19 patients were frequent but most commonly mild. AST, but not alanine transaminase, was associated with worse clinical outcomes, such as COVID-19 severity and mortality, probably indicating these outcomes were independent of liver injury. A low prevalence of CLD was seen, and a clear impact on COVID-19 outcomes was not seen.

Indexed as

Chronic liver diseaseCirrhosisCOVID-19LiverSARS-CoV-2

Identifiers

PMID34192127
PMCPMC7900474
OpenAlexW3119985798

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.